1. Sequential early-life viral infections modulate the microbiota and adaptive immune responses to systemic and mucosal vaccination.
- Author
-
Li Y, Molleston JM, Lovato C, Wright J, Erickson I, Bui D, Kim AH, Ingle H, Aggarwal S, Nolan LS, Hassan AO, Foster L, Diamond MS, and Baldridge MT
- Subjects
- Animals, Mice, Gastrointestinal Microbiome immunology, Antibodies, Viral immunology, Antibodies, Viral blood, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, Female, Microbiota immunology, Administration, Intranasal, Mice, Inbred C57BL, Immunity, Mucosal immunology, Adaptive Immunity immunology, SARS-CoV-2 immunology, COVID-19 immunology, COVID-19 prevention & control, Vaccination
- Abstract
Increasing evidence points to the microbial exposome as a critical factor in maturing and shaping the host immune system, thereby influencing responses to immune challenges such as infections or vaccines. To investigate the effect of early-life viral exposures on immune development and vaccine responses, we inoculated mice with six distinct viral pathogens in sequence beginning in the neonatal period, and then evaluated their immune signatures before and after intramuscular or intranasal vaccination against SARS-CoV-2. Sequential viral infection drove profound changes in all aspects of the immune system, including increasing circulating leukocytes, altering innate and adaptive immune cell lineages in tissues, and markedly influencing serum cytokine and total antibody levels. Beyond changes in the immune responses, these exposures also modulated the composition of the endogenous intestinal microbiota. Although sequentially-infected mice exhibited increased systemic immune activation and T cell responses after intramuscular and intranasal SARS-CoV-2 immunization, we observed decreased vaccine-induced antibody responses in these animals. These results suggest that early-life viral exposures are sufficient to diminish antibody responses to vaccination in mice, and highlight the potential importance of considering prior microbial exposures when investigating vaccine responses., Competing Interests: M.S.D. is a consultant for Inbios, Vir Biotechnology, Ocugen, Topspin Therapeutics, GlaxoSmithKline, Allen & Overy LLP, Moderna, and Immunome. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Vir Biotechnology, Emergent BioSolutions, and Moderna., (Copyright: © 2024 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF